Latest News in the Business and Financial World

Monday, March 1, 2021
Log in
  • Home
  • Company News & Financials
  • OTC Markets
  • Tech & Science
  • Health & LifeStyle
  • About WS OTC
    • Analysts & Contributors
    • Contact Us
    • Advertising
    • Feedback
    • Privacy Policy GDPR
  • Mobile
  • Latest News
    • New Theories Explain the Disappearance of the Mayan Civilization
    • What Happens If Coral Reefs Die?
    • Monsanto Loses Lawsuit for its Herbicide Products
    • Mankind (MNKD) shares Plunge after FDA Approves Afrezza, inhaled Insulin for Diabetes patients
    • Psychologists Confirm that Violent Video Games Boost Aggressiveness
    • World of Warcraft: Warlords of Draenor Release Date on Nov 13
    • iPass Global Hotspot Map Unveils Worldwide Wi-fi Coverage

Pages

  • About Wall Street OTC
  • Advertising
  • Analysts & Contributors
  • Contact
  • Feedback
  • Mobile
  • Privacy Policy GDPR
  • Terms of Service

Recent Posts

  • SF Hospital Slaps New Parents with $19K Bill for Baby Treatment
  • Furious Trump Blasts Harley-Davidson for Moving Production Overseas
  • Warning! MRI Machines Could Poison You
  • Flight Attendants More Likely to Get Certain Cancers
  • More Red Meat Allergy Cases Related to Lone Star Tick Bites

Two Alzheimer’s Experimental Drugs Promise Slower Progression

Jul 23, 2015 By Christina Langfold Leave a Comment

Email, RSS Follow
Eli Lilly & Co.'s and Biogen's experimental drugs might work for reducing the loss of cognitive function related to Alzheimer's, yet each come with drawbacks

Two Alzheimer’s Experimental Drugs Promise Slower Progression

On Wednesday, Eli Lilly & Co. released new data on the experimental Alzheimer’s drug – solanezumab – which raises hopes that it could be effective in treating the neurodegenerative disease.

Another set of data was released on Biogen’s experimental Alzheimer’s drug, aducanumab. The two reports are mirroring the frustrating search for treatments that could slow Alzheimer’s progression and the lengthy process of clinical trials.

Eli Lilly & Co.’s drug, as well as Biogen’s are targeting the amyloid plaques building up on the brain. Recently these have become the center of attention in what could be the potential spark of Alzheimer’s disease.

With five million U.S. citizens affected by the disease, the search for effective treatments is an ongoing struggle. As of yet, the majority of experimental drugs have failed in reducing the cognitive function loss characteristic to Alzheimer’s disease.

In 2012, Eli Lilly & Co. reported a resounding failure connected to solanezumab use on Alzheimer’s patients that were already in the mild to moderate stages. For mild stage Alzheimer’s patients, the drug had yielded some results, thus a new clinical trial was initiated, this time targeting exclusively this group. Until 2017, there will be no final results.

Yet, the data released on solanezumab on Wednesday is preliminary from the second clinical trial. After the first 18-month test was ended, the patients in the mild stage group, as well as those in the placebo receiving group were asked if they wished to continue treatment with the drug.

The test was randomized, meaning neither doctors nor patients knew which patient had been in which group initially. Thus, some would continue from the 18 months treatment with solanezumab, some would just start and some would end treatment and receive placebo.

The idea that the study was built on is that if solanezumab is efficient in slowing cognitive function loss, then the patients that had only received placebo drugs would not be able to catch up with those that received Eli Lilly & Co.’s drug throughout the entire 18 months study.

Indeed, there was a statistically significant difference between the two groups, which persisted for one more year in the new study, and reduced significantly during the second year. These are signs of success according to the researchers involved in the study, yet they should be treated with caution.

Some have already voiced their cautious opinion. Professor Dr. Lon Schneider of the University of Southern California stated:

“The statistical analysis reported today does not provide any information on efficacy or on the amyloid hypothesis”.

Financial analysts have also taken an interest in the matter. Vamil K. Divan of Credit Suisse, noted for the New York Times that:

“today’s results at least allow investors to maintain hope that this potentially transformative product may make it to the market”.

Biogen on the other hand, had more successful results in March with its aducanumab experimental Alzheimer’s drug. While highly successful in slowing down the loss of cognitive function, this came at a cost. In order to achieve the results, the dose of aducanumab was increased to the point where it lead to a dangerous side effect: local swelling in the brain.

Biogen stated that it had adjusted the dose to medium and 30 patients who were receiving it showed the same results in slowing the rate of cognitive function loss, while presenting fewer side effects. This didn’t last for long, as medium dose was shown to not reduce cognitive function loss in a significant manner during one year of further study, while side-effects were still often reported.

Following the reports on Wednesday, Eli Lilly & Co. shares saw an increase of 1 percent, while Biogen’s shares declined by 4 percent.

Photo Credits csmres.co.uk

Email, RSS Follow
The following two tabs change content below.
  • Bio
  • Latest Posts

Christina Langfold

Remember that weird girl in school who never quite managed to fit in? Who was always silent and strange? That was me during my entire teenage life. A few years after finishing college (with a degree in arts) I decided that the best way to become more sociable, while also feeling safe, is to test my people skills online.

Latest posts by Christina Langfold (see all)

  • Scientists Discover the Second Fastest Spinning Pulsar In The Universe - Sep 9, 2017
  • Coral Reef Damage Scares Florida Keys Researchers and Businesses - Jun 26, 2017
  • Nike to Slash Global Workforce by 1,400 - Jun 16, 2017

Filed Under: Health & LifeStyle

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 72 other subscribers

Mom holding newborn's hands

SF Hospital Slaps New Parents with $19K Bill for Baby Treatment

Jun 29, 2018 By Anne-Marie Jackson Leave a Comment

Harley-Davidson biker

Furious Trump Blasts Harley-Davidson for Moving Production Overseas

Jun 28, 2018 By Anne-Marie Jackson Leave a Comment

MRI machine

Warning! MRI Machines Could Poison You

Jun 27, 2018 By Anne-Marie Jackson Leave a Comment

Flight Attendants More Likely to Get Certain Cancers

Jun 27, 2018 By Anne-Marie Jackson Leave a Comment

Lone star tick sitting on a succulent leaf

More Red Meat Allergy Cases Related to Lone Star Tick Bites

Jun 26, 2018 By Anne-Marie Jackson Leave a Comment

Time magazine cover

Time Admits Sobbing Cover Girl Was Not Separated from Parents

Jun 26, 2018 By Anne-Marie Jackson Leave a Comment

Sunshine and green leaves

Vitamin D Deficiency Could Boost Risk of Lung Disease

Jun 25, 2018 By Anne-Marie Jackson Leave a Comment

Green-light laser pointer

Greek Boy’s Retina Severely Damaged by Laser Pointer

Jun 22, 2018 By Anne-Marie Jackson Leave a Comment

Red Tesla car

Tesla Suing ‘Whistleblower’ over Data Theft

Jun 21, 2018 By Anne-Marie Jackson Leave a Comment

Boiled eggs and mayonnaise

Eating too Clean Can Lead to Orthorexia

Jun 20, 2018 By Anne-Marie Jackson Leave a Comment

NYC mayor Bill de Blasio

NYC Will Allow People to Smoke Pot in Public

Jun 20, 2018 By Anne-Marie Jackson Leave a Comment

A kitten and a puppy sleeping in a bed while hugging each other

Who Is Smarter Between Cats and Dogs? Researchers Have an Answer (Study)

Jun 19, 2018 By Anne-Marie Jackson Leave a Comment

Orthodox church in Greece

Being Religious Is Tied to Longer Lifespan, Study

Jun 19, 2018 By Anne-Marie Jackson Leave a Comment

Bacon and eggs for breakfast

How Does the Keto Diet Work?

Jun 18, 2018 By Anne-Marie Jackson Leave a Comment

Related Articles

  • Mom holding newborn's hands

    SF Hospital Slaps New Parents with $19K Bill for Baby Treatment

    Jun 29, 2018
  • MRI machine

    Warning! MRI Machines Could Poison You

    Jun 27, 2018
  • Lone star tick sitting on a succulent leaf

    More Red Meat Allergy Cases Related to Lone Star Tick Bites

    Jun 26, 2018
  • Sunshine and green leaves

    Vitamin D Deficiency Could Boost Risk of Lung Disease

    Jun 25, 2018
  • Green-light laser pointer

    Greek Boy’s Retina Severely Damaged by Laser Pointer

    Jun 22, 2018
  • Boiled eggs and mayonnaise

    Eating too Clean Can Lead to Orthorexia

    Jun 20, 2018
  • Orthodox church in Greece

    Being Religious Is Tied to Longer Lifespan, Study

    Jun 19, 2018
  • Office workers

    Free Workplace Food Is Packed with Empty Calories (Study)

    Jun 13, 2018
  • Basil leaves in a wooden spoon next to some cherry tomatoes

    Plant Foods Are the Secret to Longevity and a Healthy Life

    Jun 12, 2018
  • hotel room

    Scientists Paying Volunteers $3,500 to Stay at ‘Flu Hotel’

    Jun 11, 2018

Categories

  • Business
  • Company News & Financials
  • Diversified Financial
  • Entertainment
  • Featured
  • Health & LifeStyle
  • Micro Cap
  • Mid Cap
  • National News
  • Nature
  • OTC Exchange
  • OTC Markets
  • OTC Research
  • Science
  • Small Cap
  • Sports
  • Tech & Science
  • U.S.
  • Uncategorized
  • Wall Street
  • World
  • World Indexes

Copyright © 2021 wallstreetotc.com

About · Privacy Policy · Sitemap · Terms of Service · Contact

This website uses cookies to ensure you get the best experience on our website. Learn more.